Quantitative real-time polymerase chain reaction analysis of the type distribution, viral load, and physical status of human papillomavirus in liquid-based cytology samples from cervical lesions

International Journal of Gynecological Cancer

Volumn 18, Issue 1, 2008, Pages 121-127

  Yoshida, T ^a   Sano, T ^a   Kanuma, T ^a   Owada, N ^a   Sakurai, S ^a   Fukuda, T ^a   Nakajima, T ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Human papillomavirus (HPV); Liquid based cytology (LBC); Physical status; Viral load

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER SCREENING; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; JAPAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD; WART VIRUS;

ADULT; AGED; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; GENE DOSAGE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 38049062239     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00979.x     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 : 55 : 74 108.
2. Dueñas-González A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 2005 4 : 1 24.
3. Muñoz N, Bosch FX, De Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 348 : 518 27.
4. Bulkmans NW, Rozendaal L, Voohorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005 92 : 1800 2.
5. Wright Jr. TC, Schiffman M, Solomon D et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. ACOG 2004 103 : 304 9.
6. Lörincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening. Arch Pathol Lab Med 2003 127 : 959 68.
7. Peitsaro P, Johansson B, Syrjänen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by novel quantitative real-time PCR technique. J Clin Microbiol 2002 40 : 886 91.
8. Lörincz AT, Castle PE, Sherman ME et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. THE LANCET 2002 360 : 228 9.
9. Gravitt PE, Burk RD, Lorincz A et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. CEBP 2003 12 : 477 84.
10. Dalstein V, Riethmuller D, Prétet JL et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003 106 : 396 403.
11. Joseffson AM, Magnusson PK, Ylitalo N. A higher level of human papillomavirus 16 DNA was associated with an increased risk for cervical carcinoma in situ. EBM 2001 6 : 29.
12. Ylitalo N, Sorenson P, Josefsson AM. Persistently high loads of human papillomavirus 16 over time were associated with an increased risk for cervical cancer. EBM 2001 6 : 30.
13. Josefsson AM, Magnusson PKE, Ylitalo N et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. THE LANCET 2000 355 : 2189 93.
14. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL. Dynamics of HPV 16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006 35 : 270 7.
15. Casas L, Galvan SC, Ordonez RM, Lopez N, Guido M, Berumen J. Asian-American variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas. Int J Cancer 1999 83 : 449 55.
16. Crusius K, Auvinen E, Alonso A. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997 16 : 1437 44.
17. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987 61 : 962 71.
18. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increase viral immortalization capacity. Proc Natl Acad Sci USA 1992 89 : 3159 63.
19. Howley PM, Sceffner M, Huibregtse J, Munger K. Oncoproteins encoded by the cancer-associated human papillomaviruses target the products of the retinoblastoma and p53 tumor suppressor genes. Cold Spring Harb Symp Quant Biol 1991 56 : 149 55.
20. Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U, Johansson B. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). BJC 2005 92 : 2195 200.
21. Kulmala S-MA, Syrjänen SM, Gyllensten UB et al. Early integration of high copy HPV 16 detectable in women with normal and low grade cervical cytology and histology. J Clin Pathol 2006 59 : 513 7.
22. Garbar C, Mascaux C, Fontaine V. Efficiency of an inexpensive liquid-based cytology performed by cytocentrifugations: a comparative study using the histology as reference standard. CytoJournal 2005 2 : 15.
23. Fujii T, Masmoto N, Saito M et al. Comparison between in situ hybridization and real-time PCR technique as a means of detecting the integrated form of human papillomavirus 16 in cervical neoplasia. Diagn Mol Pathol 2005 14 : 103 8.
24. Fujinaga Y, Shimada M, Okazawa K, Fukushima M, Kato I, Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol 1991 72 : 1039 44.
25. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA residual material from Thinprep papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002 8 : 2199 210.
26. Masmoto N, Fujii T, Ishikawa I et al. Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women; study of 881 outpatients. Gynecol Oncol 2004 94 : 509 14.
27. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H. Detection and typing of multiple genital human papillomavirus by DNA amplification with consensus primers. Jpn J Cancer Res 1991 82 : 524 31.
28. Munoz N, Kato I, Bosch FX et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996 23 : 504 10.
29. Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste. Costa Rica. J Infect Dis 2005 191 : 1808 16.
30. Kulasingam SL, Hughes JP, Kiviat NB et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. JAMA 2002 288 : 1749 57.
31. Ylitalo N, Josefsson A, Melbye M et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000 60 : 6027 32.
32. Nagao S, Yoshinouchi M, Miyagi Y et al. Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR. J Clin Microbiol 2002 40 : 863 7.
33. Wagatsuma M, Hashimoto K, Matsukura T. Analysis of integrated human papillomavirus type 16 DNA in cervical cancers: amplification of viral sequences together with cellular flaking sequences. J Virol 1990 64 : 813 21.